2005
DOI: 10.1093/rheumatology/kei171
|View full text |Cite
|
Sign up to set email alerts
|

Chondroprotective drugs in degenerative joint diseases

Abstract: Catabolic cytokine and anabolic growth factor pathways control destruction and repair in osteoarthritis (OA). A unidirectional TNF-alpha/IL-1-driven cytokine cascade disturbs the homeostasis of the extracellular matrix of articular cartilage in OA. Although chondrocytes in OA cartilage overexpress anabolic insulin-like growth factor (IGF) and its specific receptor (IGFRI) autocrine TNF-alpha released by apoptotic articular cartilage cells sets off an auto/paracrine IL-1-driven cascade that overrules the growth… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
55
0
7

Year Published

2006
2006
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 136 publications
(62 citation statements)
references
References 117 publications
0
55
0
7
Order By: Relevance
“…In particular, IL-1b induces production of collagenase by synovial cells and of metalloproteinases by chondrocytes. 26 Another important characteristic of IL-1b is its toxicity for insulin-producing b-cells in Langerhans islets, supporting a role of IL-1b in the pathogenesis of insulin-dependent type I diabetes. 27,28 Similarly, IL-1b may be toxic for neurons and is involved in acute neurodegeneration and stroke.…”
Section: Caspase-1 and It Substrate Il-1bmentioning
confidence: 97%
“…In particular, IL-1b induces production of collagenase by synovial cells and of metalloproteinases by chondrocytes. 26 Another important characteristic of IL-1b is its toxicity for insulin-producing b-cells in Langerhans islets, supporting a role of IL-1b in the pathogenesis of insulin-dependent type I diabetes. 27,28 Similarly, IL-1b may be toxic for neurons and is involved in acute neurodegeneration and stroke.…”
Section: Caspase-1 and It Substrate Il-1bmentioning
confidence: 97%
“…Currently there exists no accepted medical treatment with structure or disease modification in OA (24)(25)(26)(27)(28)(29)(30)(31), despite the high and vastly increasing number of patients with a need to be treated. In this context, quantitative MRI can help to identify promising drug targets (by identifying tissue components that change first and are responsible for changes in other tissues) and, in particular, to monitor structural effects of drugs in order to prove their effectiveness.…”
Section: Rationale For Quantitative Mri Of Cartilage and Bone In Ostementioning
confidence: 99%
“…Hence, there has been a continuous search for new and better drugs for OA. There has been increase in the use of symptomatic slow acting drugs such as glucosamine, CS and diacetylrhein (diacerein) [7]. These drugs could favor anabolic processes in the OA cartilage and contribute to a delayed progression of the disease via inhibition of the catabolic processes [8].…”
mentioning
confidence: 99%